• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Terumo (TSE:4543) Stock Catches Up To A Sharper Margin Story

    Simply Wall St·08/09/2026 00:22:08
    语音播报

    Terumo stock went into this print with a solid recent run and a P/E that sat roughly in line with peers but above the broader Japanese medical equipment group. The headline from Q1 2027 is simple: profit quality surprised more than price. Basic earnings per share of ¥47.74 and net income of ¥70,426m landed on top of a ¥311,810m revenue base, underscoring earnings strength that the share price at ¥2,373 may not fully reflect yet.

    Impressed by Terumo's earnings strength but want stocks where profit quality already lines up cleanly with the current share price? Take a look at our 18 high quality undervalued stocks for ideas that combine solid fundamentals with potentially more attractive valuations.

    Q1 2027 Earnings Summary

    • Revenue, Q1 2027 vs. Q1 2026: ¥311,810 million vs. ¥259,965 million (up about 20.0%)
    • Net Income, Q1 2027 vs. Q1 2026: ¥70,426 million vs. ¥41,843 million (up about 68.3%)
    • Basic EPS, Q1 2027 vs. Q1 2026: ¥47.74 vs. ¥28.37 (up about 68.3%)
    • Trailing 12-month Net Income, Q1 2027 TTM vs. Q1 2026 TTM: ¥164,497 million vs. ¥124,930 million (up about 31.7%)

    Prefer clear charts instead of searching through dense earnings tables and PDFs? View Terumo's complete financial picture, including a focused valuation snapshot, in the visual company report for Terumo.

    TSE:4543 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
    TSE:4543 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

    Terumo’s Bull Case: Margin Story Starts To Show Up

    Bullish investors argue that Terumo can turn product innovation and manufacturing efficiency into sustained market share gains and stronger margins. Q1 2027 gives some support to that view. Net income of ¥70,426 million on revenue of ¥311,810 million points to healthier profitability than a year ago, which lines up with the claim that the Rika plasma ramp and better yields are beginning to add operating leverage.

    The bull case also leans on a broader, higher value product mix. Here, the earnings strength looks consistent with management’s push into next generation devices and CDMO (contract development and manufacturing organization) partnerships, even though the report does not break out individual product lines. The appointment of a seasoned Terumo leader to head OrganOx shows the transplant platform is being treated as a serious growth pillar. That is an important milestone for the longer term therapy portfolio story.

    Compare Terumo's margin story and product mix shift with what institutional analysts are signaling. Reveal the consensus price target analysis for Terumo to see whether the street is leaning into this earnings strength or fading it.

    Terumo Bear Case: Pricing Fears Still Unproven

    The bearish view on Terumo centers on two ideas. First, structural pricing pressure in markets like China and in mature cardiovascular and blood businesses could cap growth. Second, rising costs from supply chains and competition could cap margins.

    The latest quarter shows stronger net income and earnings per share on a larger revenue base. That undercuts the claim that pricing pressure is already eroding profitability. There is no fresh evidence in these numbers that volume based procurement in China or group purchasing is biting hard enough to stall earnings.

    However, the bears' key milestones are mostly still untested. Management has not yet provided detailed disclosure on pricing trends by region, exposure to reimbursement changes, or a clear bridge that explains how much of the margin improvement comes from sustainable product mix versus temporary cost factors. Until those details are spelled out, the structural risk argument is not disproved; it is simply not confirmed by this set of results.

    After a quarter where Terumo’s reported margins look stronger but the pricing and reimbursement picture remains opaque, you may want to review whether these results mask deeper structural pressure points and execution risks. Expose potential hidden fault lines and see how they score in our risk analysis for Terumo which shows 1 important warning sign.

    Stay Ahead Of Your Next Move

    If Terumo's profit quality and margin story has caught your attention, register for free with Simply Wall St and add it to your Watchlist to track its share price against fair value and watch for a potential entry point that fits your plan. Once you hold Terumo or other stocks, use the Portfolio Command Center to cut through noise and focus on the updates that actually matter to your thesis. For longer term conviction, tap into the Community to see how other investors are thinking about the same risks and catalysts. This way you can spot hidden strengths and emerging red flags early and keep a step ahead of the wider market.

    Seeking Alternatives Beyond Terumo Stock?

    Fresh ideas often move first when momentum builds and quality companies are still flying under the radar for now. Scan these themed shortlists before the crowd catches up and act now.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.